We are thrilled to announce that CABS will host the 2024 BioPacific Conference (The 24th Annual Conference of CABS) on October 28th, 2024, at the South San Francisco Convention Center. This year is significant as it marks the 26th anniversary of CABS. We look forward to welcoming you to this exciting conference and celebrating our quarter-century milestone together.
www.cabsweb.org; www.biopacificconference.org;
For sponsorship opportunities: fundraising@cabsweb.org
South San Francisco Convention Center
Introduction:
What does it take to bring clinical evidence to obtain market approval? This workshop is designed to gain a “big picture” of the entire drug development process from IND to NDA/BLA. It will highlight regulatory requirements, the framework for robust study design, medical monitoring and benefit & risk assessment, and elements of clinical operations and CRO program management. Key principles and concepts will be illustrated with case studies. This workshop will provide an opportunity for CABS members who are interested in expanding professional networks to clinical development for career development, industry partnerships or strategic collaborations.
Presentation Titles and Speakers:
1. Presentation Title: Brief introduction of clinical development
Speaker: Wei Dong, MD, PhD, VP and Head of Drug Safety at Denali, 2010-2011 CABS President
2. Presentation Title: Regulatory overview: the journey from IND to NDA/BLA including case examples
Speaker: Wen Liu, PhD, VP of Regulatory Affairs, Lyell Immunopharma
3. Presentation Title: Statistical considerations in clinical trial designs
Speaker: Jing Yi, PhD, Head of Data Science and Global Development Team Leader, CARGO Therapeutics
4. Presentation Title: Clinical operations and CRO program management
Speaker: Angela Wang, Commercial Director at Novotech
5. Presentation Title: Clinical Monitoring Priorities and Responsibilities
Speaker: Harry Liu, MD, MPh, MBA, Executive Director, Clinical Development, ALX Oncology
6. Presentation Title: The science and practice of drug safety
Speaker: Wei Dong, MD, PhD, VP and Head of Drug Safety at Denali, 2010-2011 CABS President
List of Speakers:
Wei Dong, MD, PhD
VP and Head of Drug Safety at Denali
2010-2011 CABS President
Wen Liu, PhD, VP of Regulatory Affairs, Lyell Immunopharma
Jing Yi, PhD, Head of Data Science and Global Development Team Leader, CARGO Therapeutics
Harry Liu, MD, MPh, MBA, Executive Director, Clinical Development, ALX Oncology
Angela Wang, Commercial Director at Novotech,
Organizing committee:
Wei Dong, MD, PhD, VP and Head of Drug Safety at Denali, 2010-2011 CABS President
Liping Meng, PhD, Senior Scientist II at Gilead Sciences, Co-chair of CABS Science & Technology Committee
Yan Wang, PhD, Director at ChemPartner, Co-chair of CABS Science & Technology Committee
Jessica Sun, PhD, Executive Director, In Vivo Pharmacology at Terremoto Biosciences, 2024-2025 CABS President
Exclusive Sponsor:
NovoTech
Bio of Speaker:
Wei Dong is the VP and Head of Drug Safety at Denali Therapeutics where she builds and leads safety and pharmacovigilance organization. She oversees the scientific, operational and product strategy aspects of global safety during clinical development and prepare the organization as a whole to address future marketing authorization applications and multinational postmarketing safety requirements. Wei brings extensive R&D experience in global drug development to improve patient care. She held executive leadership roles in Genentech and Roche in the areas of drug safety, epidemiology and Asia Pacific product development contributing to the approval of multiple breakthrough medicines. Most recently she served as the VP and Head of Safety at Corcept Therapeutics building up its safety team and ensuring successful regulatory inspections. Wei obtained her MD from Shanghai Medical University and PhD in Epidemiology from the London School of Hygiene & Tropical Medicine, University of London. She lectured at UCL Medical School, U.K., and was an Assistant Professor of Epidemiology and Community Medicine at Mount Sinai School of Medicine before joining the industry. Wei is a long-term supporter of the CABS vision and community and has served as the CABS Present 2010-2011. )
Jing Yi is the Head of Data Science, Global Development Team Leader for CRG-022 at CARGO Therapeutics since May 2023. Jing has over 17 years of industry experience with a proven record in oncology clinical development and medical affairs, and in functional and cross-functional leadership.
Jing has been involved in many successful global regulatory interactions and approvals, including Avastin across various tumor types. She has built and led multiple high performing cross-functional teams and initiatives. Prior to joining CARGO, Jing spent over 2 years at Erasca as the Senior VP of Data Science and PTL of ERAS-601 program. Jing was the Global Development Team Leader for Tecentriq at Roche/Genentech prior to joining Erasca, where she led a cross functional team and was accountable for the overarching strategy, development and implementation of cancer immunotherapy in Lung and Head/Neck Cancers. She also managed a group of medical directors and clinical scientists. Prior to her cross-functional leadership role, she was the biometrics lead of multiple molecules and managed a group of statisticians who supported many pivotal studies at Roche/Genentech. Jing received her PhD. in Statistics from the University of California, Berkeley.
Angela Wang has extensive business development, investment, product management, and research experience in the biotech industry. As the China Commercial Director at Novotech, her focus is to bridge the needs of biopharma companies in North America/Europe with China. This involves guiding clients through regulatory, clinical, and commercialization strategies.
Angela previously held Sr. Director of Business Development position at ClinChoice, Director of Investments and Operations at several venture capital firms as well as various senior product management and marketing roles at ThermoGenesis, Thermo Fisher Scientific, and Abaxis.
Angela received her MBA from Rensselaer Polytechnic Institute and B.S. in Cell Biology from Wuhan University. Angela is based in the San Francisco Bay Area.
Wen Liu is a seasoned regulatory affairs professional in biotech. She has been serving as the VP of regulatory affairs at Lyell immunopharma since 2021, a clinical stage cell therapy company with genetic reprogramming technologies for oncology. Prior to joining Lyell, she joined Genentech in 1998 as a scientist in research after acquiring her PhD. In 2004, she transitioned to clinical regulatory affairs and over time has established as a leader in regulatory strategy and filings for groundbreaking oncology therapies. At Genentech/Roche, she was instrumental in the successful development and approval of major oncology therapies worldwide as a global regulatory affairs leader. At Lyell, she continues to drive regulatory excellence to bring transformative therapies to clinic.
Harry Liu is currently an Executive Director Clinical Development in ALX Oncology, where he is the clinical lead for the head and neck cancer programs. Prior to ALX Oncology, he had worked in Genentech and Amgen, and taken leadership roles in clinical development and clinical safety functions. Harry received his medical degree from Norman Bethune University of Medical Sciences, MPH in Epidemiology from UC Berkeley, and MBA from UCLA Anderson school.
Lunch will be provided. Limited seats. RSVP is required. Please register as early as possible.
1633 Old Bayshore Hwy #280, Burlingame, CA 94010
Please note the address has been updated to 3000 El Camino Real, Building # 5, Suite 125, Palo Alto, CA 94306.
******************************************
Call for all innovators and entrepreneurs who are looking to turn their ideas to startups!
Present your ideas to seasoned VCs, veteran BDs, and your potential co-founders– get feedbacks, funding opportunities as well as the tickets to present at CABS flagship events such as annual BioPacific Conference or Investor Forum during JPM.
Whether you are at seed run or series A/B, all stages are welcomed!
Demo day agenda:
Road show 2.30-6.30 pm, networking reception 6.30-8.00 pm
Agenda:
2.30–2.45: Check-in and social
2.45-2.55: Open remark by CABS president Dr. Jessica Sun
2.55-3: Welcome greetings by K&L (Special thanks to K&L as our exclusive event sponsor )
3–4: First Company Presentation Session (10 min presentation + 5 min Q&A)
Amberstone
Ariz
Coastar Therapeutics
DeepSeq.AI
4–4.40: First panel
4.45–5.45: Second Company Presentation Session
ReRX
Spect
SunnyBay
Synlico
5.50–6.30: Second panel
Networking reception: 6:30–8.00
Opportunity to showcase your idea in front of VCs, BDs, seasoned and first time entrepreneurs, as well as scientists with similar passion. Be ready to mix and mingle with your potential partners!
For general in-person attendance, please register at link below.
For any questions, please feel free to contact CABS at lu.lu@cabsweb.org, Lu Lu
3000 El Camino Real, Building # 5, Suite 125, Palo Alto, CA 94306
Since its inception in 2010, the Career Advisory Network (CAN) Program has evolved into a cornerstone event of the annual calendar for the Chinese American Biopharmaceutical Society (CABS). Orchestrated by the Business and Career Development (BCD) committee, CAN stands as a pivotal mentoring initiative that facilitates personalized, one-on-one mentor-mentee pairings. The program is designed to provide tailored guidance to participants, assisting them in navigating the intricacies of their professional journeys. This includes support in areas such as business development, entrepreneurship, and the pursuit of scientific careers within both academia and the private sector. On April 13, 2024, the CABS CAN program proudly launched its latest iteration with a kick off meeting at the Hanhai Silicon Valley Center, marking the beginning of another year of transformative mentorship and growth.
Jessica Sun, the 2024 CABS president, gave a brief introduction of CABS and kicked off the meeting .
Followed by a very insightful introduction from the event Sponsor - Dr. Sheng Wang from Zelixir. Zelixir is a company focused on AI-driven synthetic biology and intelligent manufacturing. By utilizing exceptional AI-driven bioengineering technology, it combines AI with synthetic biology to lead the future of extraordinary biotechnology.
Mr. Tao Huang, President and CEO of NeuCyte, served as an esteemed mentor representative. He recounted his professional journey, imparting wisdom from his own career development. Additionally, Mr. Huang offered essential guidance to the mentees on the art of effective communication with their mentors and provided strategies for attaining success in their careers.
Additionally, Professor Ruben Luo, the Assistant Professor of Pathology at Stanford University as well as the Associated Director of Clinical Chemistry Laboratory at Stanford Health Care, a fellow mentor, imparted his wisdom by sharing his personal experiences and providing insightful guidance.
Following the sharing session, mentors and mentees actively engaged with one another, reinforcing the relationships and forging new bonds.
The kickoff meeting marked a stellar beginning for the thrilling CAN initiative, leaving participants infused with a sense of empowerment and a strong motivation to drive success. We extend our heartfelt gratitude to Ava Song, Jonathan Wong, and Le Cai for their exceptional coordination efforts in launching this program.
We thank again for our exclusive sponsorship from Zelixir. More information about our sponsor can be found here: https://www.zelixir.com/
Hanhai Biolabs---1633 Old Bayshore Hwy STE 280, Burlingame, CA 94010
The Chinese American Biopharmaceutical Society (CABS) is thrilled to announce a new summer internship program focused on the cutting-edge field of data science applied to drug discovery and development.
As our industry generates unprecedented amounts of data from genomics, proteomics, clinical trials and real-world evidence, there is a growing need for talented data scientists who can derive insights to drive innovation. CABS is committed to helping bridge this talent gap and train the next generation of data leaders in biopharma.
This 10-week non-paid internship program will provide an immersive experience for undergraduate and graduate students to work alongside data science teams at top CABS member companies in the San Francisco Bay Area. Interns will get hands-on experience applying the latest machine learning, AI and data analytics tools to solve real-world challenges across all phases of the drug development lifecycle.
Not only will interns gain technical data skills, but they will also learn about the biopharma business through workshops, networking events, and mentorship opportunities with CABS member company leaders, entrepreneurs and investors.
A primary focus will be nurturing a talented and diverse pipeline of data science professionals, including those from Asian American and Pacific Islander backgrounds. In addition to students from top universities like UC Berkeley, Stanford and UCSF, we strongly encourage applications from students at universities across the Pacific Rim and Asia.
Internship Timeline:
- Applications Open: April 1, 2024
- Application Deadline: June 5th, 2024
- Internship Dates: June 15 - August 25, 2024
This internship program represents an incredible professional development opportunity. We invite all eligible students passionate about life sciences and data to apply!
For more details on the program, eligibility requirements and how to apply, please contact:
Please click this link or scan the QR code below
to finish the online application!
We look forward to receiving applications from the world's brightest data science minds!
Sincerely,
President, CABS
April, 2024
CABS, a certifying organization of President’s Volunteer Service Award (PVSA)
On March 6, 2024, Chinese American Bio/Pharmaceutical Society (CABS) was officially approved as a certifying organization empowered to confer the President’s Volunteer Service Award (PVSA). CABS will be responsible for verifying and certifying that volunteers have fulfilled the necessary requirements to qualify for the PVSA within a 12-month period (e.g., from February 16, 2024, to February 15, 2025).
Any eligible adult or student volunteer who has contributed to CABS events will be required to self-track their hours on the service log sheet. The co-chairs of each committee will oversee the review and verification process. It is imperative that volunteers diligently maintain their hours tracking records as proof during potential audits. Please use the “PVSA Service Log” as a template.
For any inquiries or clarifications, please reach out to BCD Co-chair: Lin Wang, PhD; lin.wang@cabsweb.org
You are cordially invited to attend 2024 Chinese New Year celebration party organized by the Chinese American Biopharmaceutical Society (CABS). Please come to enjoy music, singing, dancing, Guzheng (Chinese zither), martial arts and other entertainments performed by local Chinese dancers and artists, experience authentic Chinese foods, having fun solving riddles, prize draw and much more.
Please mark your calendar, and your early online registration will be greatly appreciated. We look forward to seeing you there and celebrating Year of the Dragon together!
Thanks to our sponsors(see more detail in the end):
Thanks to our sponsors:
Contact: David Ri Sun CPA&MBA, License#123434
Cell: 408-6610087
Address: 97 E. Brokaw Rd, Suite 310-F, San Jose, CA, 95112
Email: david@apobridge.com
Website: www.apobridge.com
Contact: Winny Lin MBA, LUTCF Financial Planner License#0E31564
Cell: 415-309-7300
Address: 951 Mariner Island Blvd, Suite 600, San Mateo, CA, 94404
Email: wylin@ft.newyorklife.com
Website: www.callwinny.com
%20PNG_HR.png)
GenScript is a leading provider of advanced life sciences solutions, empowering researchers worldwide to achieve breakthroughs in their scientific endeavors. With expertise in custom Gene Synthesis, Protein Expression, CRISPR Technology, Reagent Antibody Development, and Virus Packaging, GenScript offers precision-engineered tools and services to accelerate research in Genomics, Gene Cell Therapy, and Antibody-Drug Discovery. Known for reliability and innovation, GenScript is a trusted partner for scientists seeking high-quality, customized solutions to propel their experiments and discoveries forward. Explore the potential of your research with GenScript at www.genscript.com.
Name: Fiona Wu - Sales Account Manager
Cell: 732-902-1603
Email: fiona.wu@genscript.com, Website: www.genscript.com
Contact: Xingyu Shen, CEO，PhD
Cell: 510-570-9504，
Address: 1257 Magnolia Ave, San Carlos.
Email: Connect@quanmol.com
Website: www.QuanMol.com
Foster City, William E. Walker Recreation Center, 650 Shell Blvd. Foster City, CA 94404
Lunar New Year is the most important holiday celebrated by Chinese and other Asian communities globally. On February 4th, 2024, despite having the worst storm in a year in the San Francisco Bay Area, more than 250 members and friends of Chinese American Bio/Pharmaceutical Society (CABS) gathered at the Foster City Recreation Center to celebrate the beginning of the Year of Dragon. As a tradition of CABS, this gala was hosted by its Social Life Committee, featuring a wide variety of spectacular live cultural performances, traditional Chinese cuisine, and auspicious wishes.
The attendees were first greeted with vibrant decorations of red lanterns, hand-written couplets and many other festive ornaments as they entered the venue. The gala was then kicked off and livened up by the rhythmic beats and energetic movement of a traditional Chinese waist drum folk dance, symbolizing the expression of joy, luck, unity and prosperity for the new year.
There were 20 different performances at the Gala, including classical folk dances, contemporary dance, Jazz, Latin and break dances, martial arts, singings, qipao runway show, traditional Chinese stand-up comedy, as well as both modern and classical string instrument performances. The program was graciously delivered by more than 100 performers from the Bay Area, showcasing the generosity and talents of the community, as well as the rich heritage and diversity in Chinese culture.
While indulging in the dazzling performances, attendees were served with authentic Chinese dishes that symbolizes longevity, abundance, and fortune according to the Chinese Spring Festival traditions. Throughout the event, attendees were highly engaged in cultural activities such as calligraphy, learning different forms of Chinese characters and bringing home their favorite couplets expressing best wishes. At the other side of the venue, attendees were provided with opportunities to meet with our sponsors, learn about their products and services, and receive the unique giveaways.
During intermissions, 10 New Year gifts, including two grand prizes of gift card, were given out to winners from three rounds of “Lucky Draw”. The winners were picked out by the two co-chairs of the Social Life Committee, Ms. Li Wang and Ms. Katherine Guan, and distinguished guests including sponsors and the founding president of CABS, Dr. Keting Chu.
Whether it’s a festive gala, a cultural celebration or a networking event, the CABS Chinese New Year Gala provided a dynamic platform for attendees to explore the roots of Chinese culture with their family and friends, while expanding their professional connections with new friends.
CABS would like to extend its sincere appreciation to all volunteers, members, and participants for their support to make this event a huge success. A special shout-out to Li Wang, who dedicated tremendous time and effort to make this event possible. This event was sponsored by Apobridge CPA Firm, GenScript, HungryPanda, New York Life Insurance and QuanMol Tech. Thank you all for your support and we wish you joy, prosperity and success in the Year of the Dragon! Hope to see you again next year!
-
CABS is pleased to announce the awardees of the 2023 CABS Award
-
-
Congratulations to all the award winners for their outstanding achievements and contributions! Your dedication, hard work, and talent have been recognized and celebrated by all of us at CABS. We are truly grateful for your remarkable efforts, which have inspired and uplifted everyone around you. Thank you for your unwavering commitment to excellence and for being an inspiration to us all. We extend our heartfelt congratulations and best wishes for your continued success and accomplishments in the future.
-
-
This year’s annual Chinese American Bio/Pharmaceutical Society (CABS) Executive Council Transition Meeting convened on January 27th, 2024, in Burlingame. Attendees included esteemed members from both the 2023 and 2024 Executive Committees.
Setting the tone for the gathering, Dr. Yuying “Kate” You, the immediate past CABS president, artfully delineated the remarkable achievements of the year of 2023. These notable accomplishments encompassed a spectrum of successes, featuring events such as the 2023 Investor Forum, 2023 BioPacific Conference, the 25th Year Anniversary Reception, and activities as well as workshops organized by the Social Life committee, International Collaboration Committee, and Science & Technology Committee.
Speaking on behalf of the Board of Directors, Dr. Yang Tian, the former president of CABS, took the stage to elucidate the meticulous bylaws and code of conduct that guide the organization.
Dr. Jessica Sun, President-Elct of CABS 2023 and Chair of the 2023 BioPacific Conference Organizing Committee, engaged the audience with a comprehensive review of the preceding year. They shared both the triumphs and the invaluable lessons learned, casting an optimistic gaze toward the promising future of their respective committees in the upcoming year.
The transition from the 2023 EC to the 2024 EC was formally concluded as Dr. Yuying “Kate” You, the president of CABS 2023, ceremoniously passed the President’s Cup, signifying the CABS Presidency, to Dr. Jessica Sun, the newly inaugurated CABS president for 2024.
Jessica then announced the members of the 2024 CABS EC listed below:
Finally, Kay Tong, the newly elected President-Elect and Chair of the 2024 BioPacific Conference, provided insights into how the new EC will strategically prepare for the Conference.
Please join us to thank the 2022-2023 CABS EC for their excellent service and congratulate the 2024 CABS EC and wish them great success!
Hanhai Biolabs
The “Road Map for Transnational Planning” workshop hosted by the Social Life Committee (SLC) of CABS on January 20th attracted more than 40 attendees at Hanhai Biolabs in Millbrae, CA. This in-person event discussed strategic plannings designed for successful professionals and business owners to minimize tax while maximizing their foreign assets to help achieve financials goals for their family and future generations.
The workshop kicked off with our first speaker, Mr. Frank Huang, J.D. LL.M, Corporate VP and Advanced Planning Consultant, who has over 20 years of experience in estate planning, trust administration and business succession planning. During his talk, Mr. Huang elucidated the issues and process of probate in California with and without a Will. He also introduced strategic ways to avoid probate for the benefits of time, cost, and privacy.
Our second speaker, Mr. Tony Li, Corporate VP and Advanced Planning Consultant, discussed the upcoming changes in the federal tax system and the reporting requirements of foreign estates for U.S. citizens and residents, highlighting the benefits of leveraging a team of experienced financial professionals and attorneys for designing personalized financial plans.
Finally, Ms. Winny Lin, MBA, LUTCF, Financial Planner and Investment Advisor, shared two case scenarios in which her high-income clients successfully retain legacy control over their multi-million foreign assets while minimizing tax liabilities for their heirs and beneficiaries through advanced estate and trust planning.
Speakers received many follow-up questions from the highly engaged audience during the workshop, reflecting widespread of interest on the topics being discussed. This event marks another success on CABS’s commitment to our mission of serving the community.
